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During chronic liver diseases, hepatic stellate cells (HSC)
acquire an activated myofibroblast-like phenotype, prolifer-
ate, and synthetize fibrosis components. We have shown
that endothelin-1 (ET-1) inhibits the proliferation of acti-
vated human HSC via endothelin B (ETB) receptors. We
now investigate the transduction pathway involved in the
growth inhibitory effect of ET-1 in activated HSC.
Endothelin-1 and the ETB receptor agonist, sarafotoxin-
S6C, increased synthesis of PGI2 and PGE2, leading to ele-
vation of cAMP. The cyclooxygenase inhibitor ibuprofen
and the adenylyl cyclase inhibitor SQ22536 both blunted the
growth inhibitory effect of ET-1. Analysis of early steps as-









ET-1, forskolin decreased c-jun mRNA induction without









rafotoxin-S6C, as well as forskolin, reduced activation of
both c-Jun kinase and extracellular signal-regulated kinase.
Finally, forskolin, PGI2, and PGE2 raised by fivefold the
number of ET binding sites after 6 h, and increased the pro-
portion of ETB receptors from 50% in control cells to 80%
in treated cells.
In conclusion, ET-1 inhibits proliferation of activated
HSC via ETB receptors, through a prostaglandin/cAMP
pathway that leads to inhibition of both extracellular signal-
regulated kinase and c-Jun kinase activities. Upregulation
of ETB receptors by prostaglandin/cAMP raises the possi-
bility of a positive feedback loop that would amplify the
growth inhibitory response. These results suggest that ET-1
and agents that increase cAMP might be of interest to limit
proliferation of activated HSC during chronic liver diseases.
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 are a family of three homologous peptides
(ET-1, ET-2, and ET-3) that display a wide variety of biologi-
cal activities (1) such as vasoconstriction (2), glycogenolysis
(3–5), and positive (6) or negative (7) effects on cell growth.
The peptides bind at least three G protein–coupled receptors,
which have been cloned. The ETA receptor binds ET-1 with a
higher affinity than ET-3, the ETB receptor displays a similar
high affinity for both peptides, and the ETC receptor exhibits
a higher affinity for ET-3 than ET-1 (8, 9). In keeping with the
pleiotropic functions of ETs, stimulation of ET receptors is
coupled to several transduction pathways, including calcium,
nitric oxide, arachidonic acid, and cyclic AMP (8, 10).
Hepatic stellate cells (HSC, also known as lipocytes, fat-
storing cells, or perisinusoidal cells) play a crucial role in the
development of liver fibrosis (11). After acute or chronic liver
injury, HSC transdifferentiate to an activated myofibroblastic
phenotype (12), proliferate, accumulate, and secrete compo-
nents of fibrosis (11). Activated HSC display a high number of
ET binding sites (7, 13) that mediate at least two biological ef-
fects of ET-1, contraction (14, 15) and growth inhibition (7). In
human activated HSC, ETA receptors are responsible for con-
traction via a calcium-dependent pathway (16), and we have
shown that ETB receptors mediate the antiproliferative effect
of ET-1 (7). The aim of the present study was to determine the
second messenger responsible for the antiproliferative effect
of ET-1, and to investigate its mechanism of action. We show
that activation of the ETB receptor stimulates the production
of prostaglandins, leading to an increase in cAMP, which in
turn inhibits cell proliferation. Stimulation of the cAMP path-
way by ET-1 reduces activation of both extracellular signal-





nase (JNK). In addition, both cyclic AMP and prostaglandins
markedly upregulate ETB binding sites, suggesting the possi-






ET-1 and Sarafotoxin-S6C (SRTX-C) were from Neosys-
tem (Strasbourg, France), SQ 22536 from Biomol (Tebu, Le Perray
en Yvelines, France). Forskolin (Sigma Chemical Co., L’Isle d’Abeau
 
Address correspondence to Sophie Lotersztajn, Unité INSERM 99,
Hôpital Henri Mondor, 94010 Créteil, France. Phone: 33 1 49 81 35
34; FAX: 33 1 48 98 09 08; E-mail: loterszt@anatole.im3.inserm.fr
 
Received for publication 13 March 1996 and accepted in revised




Abbreviations used in this paper:
 
 ERK, extracellular signal-regu-
lated kinase; ET, endothelin, G3PDH, glyceraldehyde-3-phosphate








Chesnes, France) was dissolved in dimethylsulfoxide. Ibuprofen, pros-
taglandin E2, and carbacyclin, the stable analog of prostaglandin I2,


















(5,000 Ci/mmol) were from Amersham (Les Ulis, France). Fetal calf
serum was from JBio Laboratories (France). Pooled human AB posi-
tive serum was supplied by the National Transfusion Center. cDNAs
encoding mouse c-fos and c-jun were kindly provided by Dr. Yaniv
(Institut Pasteur, Paris, France) and the human krox-24 probe was a
generous gift of Dr. Casellas (Sanofi, Montpellier, France).
 
Cell isolation and culture. 
 
Human HSC were obtained in their
activated phenotype by outgrowth from explants of normal liver ob-
tained after surgery of benign or malignant liver tumors. This proce-
dure is in accordance with ethical regulations imposed by French leg-
islation. Explants were incubated, as described previously, in DMEM
containing 10% serum (5% fetal calf serum/5% pooled human se-
rum), thereafter referred to as DMEM 5/5 (17). Exhaustive charac-
terization of these cells has already been published (17). All cell iso-





-actin, a marker of HSC in their myofibroblastic phenotype.
Experiments were performed between passages 3 and 8, without any
noticeable difference in results observed with cells from various pas-
sages, or obtained from various livers.
 
Cyclic AMP assay. 
 
Confluent cells in 24-well plates were serum
starved in Waymouth medium over 48 h. After preincubation with 1
mM iso-butyl-methyl-xanthine for 15 min, cells were stimulated in
PBS with indicated effectors, over 5 min (unless otherwise specified).
Assays were performed in duplicate. Cyclic AMP was extracted in













assay. Cyclic AMP was assayed by a commercial radioimmunoassay
(Amersham). When indicated, cells were pretreated with 1 mM SQ
22536 or vehicle. As reported by Haraguchi et al., SQ 22536 cross-
reacted with the cAMP assay; hence, calculations were performed as
described (18).
 
Adenylyl cyclase activity of a particulate fraction of HSC. 
 
A par-
ticulate fraction of HSC was obtained from confluent, quiescent cells
as previously described (7). Briefly, cells were washed twice in PBS,








C, homogenized three times
with a Polytron homogenizer for 10 s, and subsequently centrifuged




 The pellet was resuspended in 50 mM Hepes,
pH 7.4, and stored in liquid nitrogen. Adenylyl cyclase activity was








Confluent quiescent cell monolayers in
24-well plates were washed twice in PBS and further incubated over
various periods of time (0–30 min) with 100 nM SRTX-C or ET-1. Su-













 (the stable breakdown product of PGI2) were assayed by a





 and PGE2 was monitored in the absence or pres-
ence of 100 nM SRTX-C and results were expressed as percent in-
crease from control levels. During the incubation period, spontane-




 and PGE2 increased
progressively, achieving 23 and 46.3 ng/mg proteins after 30 min, re-
spectively.
 
DNA synthesis assay. 
 
DNA synthesis was measured in triplicate




H]thymidine, as previously described (7).
Confluent cells in 96-well plates were made quiescent in serum-free
Waymouth medium over 3 d. Cells were stimulated for 30h with 2%
human serum in the presence of ET-1, forskolin, or prostaglandins. In
some experiments, cells were pretreated for 30 min, with either the




M), the adenylyl cyclase in-









was added during the last 6h of incubation. Radioactivity incorpo-
rated into trichloroacetic acid–insoluble material was recovered and
measured by scintillation counting.
 
RNA preparation and Northern blot analysis. 
 
Confluent quies-
cent cells were stimulated with 5% human serum, in the absence or
presence of SRTX-C, as indicated. Total RNA was extracted in
 










lane) were denaturated, fractionated by electrophoresis through a
0.8% agarose/formaldehyde gel, and subsequently transferred to a



































sperm DNA. cDNA probes for mouse c-fos (0.5 kb NCO1 fragment),
mouse c-jun (1 kb Sma1 fragment), human glyceraldehyde-3-phos-
phate dehydrogenase (G3PDH, 1.3-kb EcoR1 fragment), and human
krox 24 (prepared from a PCR product obtained from amplification

















, krox 24, 246 bp])






P]dATP by nick translation with a commer-
cially available kit (Promega Corp., Madison, WI). Blots were subse-

















 SSC, 0.1% SDS (fos and jun




 SSC, 0.1% SDS (G3PDH and krox 24 human









C (G3PDH or krox 24). Blots were then exposed to x-ray








C. Hybridization signals were
quantified at 633 nm by scanning densitometry. Results are relative to
G3PDH expression, which was used as an internal standard to correct
for variations in loading and transfer. Autoradiograms show repre-







Extracellular signal-regulated kinase and JNK assays. 
 
Confluent
quiescent cells in 60 mm wells were stimulated for 15 min (unless oth-
erwise specified) with the indicated effectors. The reaction was termi-
nated by washing the cell cultures twice with 6 ml ice-chilled PBS.




C in 0.3 ml Hepes 50 mM, pH 7.4,





, 10 mM NaF, 0.1 mM DTT, 1 mM EGTA, 5 mM sodium



























 The supernatants were either used









Extracellular signal-regulated kinase activity was assayed in situ




g proteins) on a 10% SDS-
PAGE copolymerized with 0.5 mg/ml myelin basic protein, as previ-
ously described (7). Phosphorylated gels were exposed to x-ray films
and ERK activity was quantified by densitometry.





g cell lysates (22). JNK activity was assayed in






P]ATP of its substrate, GST-
c-Jun (1-79) fusion protein, followed by SDS-PAGE and phospho-







I]ET-1 to a particulate fraction of HSC. 
 
Confluent
quiescent HSC were incubated over various periods of time in Way-













M carbacyclin, the stable analog of PGI2. The particulate frac-





particulate fraction was performed as previously described (5).




g proteins/ml) was incu-








l Krebs-Ringer medium containing









I]ET-1 and varying concentrations of





I]ET-1 (4.5–750 pM, saturation experiments). Nonspecific binding




M unlabeled ET-1. Data
from saturation and competition experiments were analyzed using
the nonlinear regression program LIGAND.
 
Assay of protein concentration. 
 
Protein concentration was mea-
sured by the method of Bradford (23), with the exception of cell ly-
sate proteins used for ERK and JNK assays, which were assayed ac-
cording to Peterson (24).
 






Stimulation of the ETB receptor raises cyclic AMP levels
through the release of prostaglandins in activated HSC. 
 
Cyclic
AMP has been reported to cause growth inhibition in certain
mesenchymal cells (25, 26). Since we have shown that ETB re-
ceptors mediate the growth inhibitory effect of ET-1 in acti-
vated HSC, we investigated the effect of ETB receptor stimu-
lation on cAMP levels. To that aim, HSC were stimulated with
the selective ETB receptor agonist SRTX-C (27). Sarafotoxin-
S6C transiently raised intracellular cAMP, a five- to sevenfold





agonist ET-1 (100 nM) also increased cAMP concentration




). We next assayed adenylyl cyclase activity in
a particulate fraction prepared from cultured activated HSC.
Surprisingly, addition of 100 nM ET-1 or SRTX-C to the par-
ticulate fraction did not affect adenylyl cyclase activity, al-
though the enzyme was functional, responding to the pharma-
cological agent forskolin and to the physiological agonist




). These results indicate that ET-1 and SRTX-
C increase cAMP by an indirect mechanism in activated HSC.
Since ET-1 stimulates the cyclooxygenase pathway in sev-
eral cell types (8), we assessed whether ET-1 elevates cAMP
through the production of prostaglandins. Pretreatment of
HSC with the cyclooxygenase inhibitor ibuprofen blunted ET-




). Among the ma-
jor cyclooxygenase products, both PGE2 and the stable PGI2
analog, carbacyclin, increased intracellular cAMP by 3.5- and














 (the stable metabolite of PGI2) was stimulated by









 and PGE2 was maximally in-





 and PGE2 synthesis by ET-1 fol-
lowed a similar time course (not shown). Ibuprofen totally
























). It may be suggested that transient elevation of
cAMP in spite of a prolonged enhancement of prostaglandin
secretion may be related to desensitization of PG receptors (28).
Taken together, these results indicate that, in activated
HSC, stimulation of the ETB receptor increases cAMP indi-
rectly, through the release of prostaglandins.
 
The growth inhibitory effect of ET-1 is mediated by a pros-
taglandin/cAMP pathway. 
 
The growth inhibitory effect of
ET-1 was reproduced by forskolin, PGE2, and PGI2, each of
which inhibited DNA synthesis of serum-stimulated HSC by








). Moreover, pretreatment of cells with
the adenylyl cyclase inhibitor SQ 22536 suppressed the inhibi-





that SQ 22536 prevented the increase in cAMP induced by 100




M forskolin (1.8- and 2.8-fold, respectively,
as compared with 5.1-fold in the presence of ET-1 alone and
57.4-fold in the presence of forskolin alone). Blockade of the
cyclooxygenase pathway by ibuprofen also blunted the growth




). Taken together, these re-
sults show that prostaglandin-induced accumulation of cAMP
is responsible for the antiproliferative effect of ET-1 in acti-
vated HSC.
 
Selective inhibition of c-jun mRNA expression by cAMP.
 
A peculiar aspect of ET-1 signaling in activated HSC is that
stimulation of the ETB receptor selectively reduces c-jun
mRNA induction by serum, without affecting that of c-fos and
krox 24 (egr-1) mRNAs (7). The addition of forskolin to se-
rum-stimulated cells also reduced by 50% maximal induction
Figure 1. Stimulation of the ETB receptor raises cAMP indirectly by 
increasing the production of prostaglandins. (A) Effect of SRTX-C 
on cAMP levels (time course). Confluent quiescent activated HSC 
were incubated with 100 nM SRTX-C for various periods of time. Cy-
clic AMP was assayed as described in Methods. Results of a typical 
experiment repeated twice are expressed as fold over basal levels (17 
fmol cAMP/mg protein). (B) Adenylyl cyclase activity in a particulate 
fraction of activated HSC. Adenylyl cyclase activity was assayed in a 
particulate fraction prepared as described in Methods. The assay me-
dium contained 10 mM GTP, 10–20 mg protein and either 100 nM ET-1, 
100 nM SRTX-C, 30 mM PGE2, or 10 mM forskolin. Results are the 
mean6SEM from triplicate determinations of a typical experiment 
repeated twice. (C) Indirect effect of ET-1 on cAMP levels. (Black 
bars) Confluent quiescent cells were exposed for 5 min to 100 nM 
ET-1, after a 30 min pretreatment with 25 mM ibuprofen or vehicle. 
In the presence of ibuprofen alone, cAMP levels were 15.461.5 fmol/
mg protein. (White bars) Cells were treated for 5 min with either 30 
mM PGE2, 30 mM carbacyclin (the stable analog of PGI2), 30 mM 
PGD2, or 30 mM PGF2a. Data are the mean6SEM of three to six ex-
periments and are expressed as fold over basal levels obtained in the 
absence of added agents (2268.5 fmol/mg protein). (D) Sarafotoxin-
S6C stimulates production of PGI2 and PGE2 by activated HSC 
(time-course). Confluent quiescent cells were exposed to 100 nM 
SRTX-C over various periods of time, after pretreatment with ibu-
profen (25 mM) or vehicle. 6-keto PGF1a (the stable metabolite of 
PGI2) and PGE2 were assayed by enzyme immunoassay, in the pres-
ence or absence of ibuprofen (25 mM), as described in Methods. Re-
sults are expressed as percent increase from control and show a typi-
cal experiment repeated three times. Cyclic AMP and prostaglandin 
production were also assayed in the conditions used for the DNA 
synthesis assays; that is, using serum-stimulated cells (see Fig. 2). Se-
rum alone caused a fourfold increase in cAMP levels (basal level, 22 
fmol cAMP/mg protein) and a twofold elevation in prostaglandin pro-
duction (basal level, 12 ng PGE2/mg protein.) Nevertheless, in the 
presence of serum, SRTX-C and ET-1 increased cAMP by 2.1- and 
2.6-fold as compared with levels observed in serum alone (88 fmol/mg 
protein); in the presence of serum, SRTX-C increased prostaglandin 
production by 1.9-fold (serum alone, 23 ng/mg protein).
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of c-jun mRNA expression and did not modify induction of
c-fos and krox 24 mRNAs (Fig. 3). Forskolin alone did not af-
fect basal expression of c-jun, c fos, or krox 24 mRNAs in qui-
escent serum-starved cells. Hence, like ET-1, cAMP elicits dif-
ferential regulation of immediate-early gene expression in HSC.
Endothelin-1 and cAMP inhibit two members of the mito-
gen-activated protein kinase superfamily, JNK and ERK. ERK
and JNK belong to two parallel cascades that lead to phosphor-
ylation of diverse transcription factors that regulate expres-
sion of immediate-early genes important for cell proliferation
(26, 29–32). We have recently shown that the antiproliferative
effect of ET-1 is associated with a reduction of ERK activation
by serum (7). Recent reports suggest that JNK may also be in-
volved in cell proliferation (33–35), and we show here that se-
rum increases JNK activity by 10.662.0-fold after 15 min (Fig.
4 A). Sarafotoxin-S6C reduces activation of JNK by serum
(Fig. 4 A), resulting in an 8063.7% inhibition of JNK activity
after 15 min. The natural agonist ET-1 also decreases by
6062.7% JNK activity in serum-stimulated cells (Fig. 4 B). In
serum-starved cells, JNK activity was either unchanged (Fig. 4,
A and B, top, typical) or slightly increased (Fig. 4, A and B,
bottom, mean, n 5 3) by ET-1 and SRTX-C.
Figure 2. Growth-inhibitory effect of ET-1 is mediated by a prosta-
glandin-induced accumulation of cAMP. (A) Effect of PGE2, PGI2, 
and forskolin (inset) on serum-stimulated DNA synthesis. Quiescent 
cells were stimulated over 30 h with 5% human serum in the presence 
of varying concentrations of PGE2 (d) and PGI2 (added in the form 
of its stable analog carbacyclin) (s) or with 10 mM forskolin (inset). 
Results are the mean6SEM of four to eight experiments. (B) The cy-
clooxygenase inhibitor ibuprofen and the adenylyl cyclase inhibitor 
SQ 22536 blunt ET-induced inhibition of DNA synthesis. Confluent 
quiescent cells were pretreated with either 25 mM ibuprofen (s), 1 
mM SQ 22536 (m), or vehicle (d). Cells were subsequently stimu-
lated over 30 h with 5 % human serum, in the presence of varying 
concentrations of ET-1. Results are the mean6SEM of three experi-
ments and are expressed as percentage of control with serum but 
without added agent. Ibuprofen and SQ 22536 alone had no effect on 
the stimulation of [3H]thymidine incorporation by serum. [3H]Thymi-
dine incorporation was determined as described in Methods.
Figure 3. Effect of forskolin on the induction of c-jun, c-fos, or krox 
24 mRNAs by serum. Quiescent cells were preincubated for 15 min 
with or without 10 mM forskolin, and then further incubated for 60 
min in medium alone or in medium containing 5% human serum, in 
the absence or presence of 10 mM forskolin. Total RNA (20 mg/lane) 
was separated on a 0.8% agarose gel, transferred to a nitrocellulose 
membrane, and hybridized with 32P-labeled cDNA probes encoding 
c-jun, c-fos, krox 24, and G3PDH, as described in Methods. (Left) 
Typical autoradiogram. (Right) Quantification of c-jun, c-fos, and 
krox 24 signals relative to G3PDH. Results are the mean6SEM of 
three experiments.
Figure 4. Endothelin-1 and
SRTX-C inhibit activation of JNK 
by serum. (A) Time course of the 
effect of SRTX-C. Confluent quies-
cent activated HSC were stimulated 
for the indicated times with 5% se-
rum alone, 5% serum and 100 nM 
SRTX-C, or 100 nM SRTX-C 
alone. JNK activity was determined 
by phosphorylation of the c-jun–
GST substrate, as described in 
Methods. (B) Effect of ET-1 on 
JNK activity. Cells were stimulated 
for 15 min with the indicated com-
pounds. Results show a typical ex-
periment that was repeated three 
times. (Top) typical autoradio-
grams. (Bottom) Quantification of 
the JNK signal (mean6SEM of 
three experiments).
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The fact that stimulation of the ETB receptor decreases ac-
tivation of both ERK and JNK by serum led us to investigate
the effects of cAMP on these two kinases. Like ET-1, forskolin
inhibited serum-stimulated JNK and ERK activities by 60 and
50%, respectively (Fig. 5). In quiescent cells, ERK activity was
unaffected by forskolin alone (Fig. 5 B), while JNK activity
was either unchanged (Fig. 5 A, top, typical) or slightly in-
creased (Fig. 5 A, bottom, mean, n 5 3).
Collectively, these data demonstrate that, in activated
HSC, a promitogenic stimulus activates both ERK and JNK,
and that the cAMP-mediated antiproliferative effect of ET-1 is
associated with an inhibition of both pathways.
Cyclic AMP and prostaglandins upregulate ETB receptors
in human HSC. Treatment of activated HSC with 10 mM for-
skolin for 24 h increased ET receptors by four- to fivefold (Fig.
6). This upregulation was not apparent after a 1-h treatment
and reached threefold after a 6-h treatment (Fig. 6 B). PGI2
(50 mM, in the form of carbacyclin) or PGE2 (50 mM) also
raised the number of ET binding sites by four and threefold,
respectively, after 24 h (Fig. 6, A and C), with a similar time
course (not shown). There was no significant change in the
molecular weight over the time course with either compound
(Fig. 6 A); after 24 h, the molecular weight for ET-1 was
30.364.8 pM (control cells), 27.462.2 pM (forskolin), 24.061.0
pM (PGE2), and 27.361.7 pM (PGI2). Competition experi-
ments using the selective ETB agonist SRTX-C, and the selec-
tive ETA antagonist BQ123, indicated that in control cells,
ETA and ETB receptors were present in a proportion of 60:40
(mean, n 5 4). This proportion varied from 50:50 to 70:30 be-
tween experiments. Forskolin markedly increased by 6.3-fold
the number of ETB receptors after 24 h; there was also a 1.9-
fold augmentation of ETA (Fig. 6 C). Similarly, treatment of
cells with PGE2 or carbacyclin, the stable analog of PGI2, re-
sulted in marked upregulation of ETB receptors (4.1- and 6.7-
fold, respectively, after 24 h), and in a modest increment of
ETA receptors (1.1- and 1.3-fold, respectively, at 24 h) (Fig. 6 C).
Discussion
In the present study, we have investigated the transduction
mechanism responsible for the ETB-mediated antiprolifera-
tive effect of ET-1 in activated human HSC. We show that
cAMP is the messenger involved, based on the following lines
Figure 5. Effect of forskolin on the activation of JNK (A) and ERK 
(B) activities. Quiescent cells were preincubated with or without 10 
mM forskolin, and then further stimulated for 15 min with 5% human 
serum alone, 5% human serum and 10 mM forskolin, or 10 mM for-
skolin alone. JNK and ERK activity were determined as described in 
Methods. (Top) Typical autoradiograms. (Bottom) Quantification of 
the JNK and of the p44erk signals (mean6SEM of three experiments).
Figure 6. Upregulation of ETB receptors by cAMP and prostaglan-
dins. (A) Forskolin and prostaglandins increase the total number of 
ET binding sites. Confluent quiescent cells were exposed either to 
medium alone, or to 10 mM forskolin or 50 mM PGI2 (added in the 
form of carbacyclin), or 50 mM PGE2 for 24 h. Binding of [125I-ET-1] 
was measured on a cell particulate fraction, as described in Methods. 
The total number of binding sites (Bmax) was determined at each time 
point by Scatchard analysis of saturation experiments performed with 
increasing concentrations of [125I-ET-1]. (B) Time-dependent effect 
of forskolin on ET binding sites. Experiments were performed as in 
(A). (C) Forskolin and prostaglandins selectively upregulate ETB re-
ceptors. ETA and ETB receptors were determined in competition ex-
periments, using the ETB receptor agonist SRTX-C and the ETA re-
ceptor antagonist, BQ 123. Results show a typical experiment 
repeated twice.
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of evidence: (a) ETB receptor stimulation increases cAMP;
(b) cAMP inhibits growth and the adenylyl cyclase inhibitor
SQ 22536 blunts the antiproliferative effect of ET-1; and (c)
like ET-1 (7), cAMP selectively inhibits c-jun mRNA induc-
tion. These results are in keeping with the known growth in-
hibitory effects of cAMP in other cells such as fibroblasts, adi-
pocytes, mesangial and vascular smooth muscle cells (25, 26).
Moreover, they also agree with the selective down regulation
of c-jun mRNA expression associated with growth inhibitory
effects of cAMP in NIH3T3 fibroblasts (36). We investigated
whether, in activated HSC, ET receptors are directly coupled
to adenylyl cyclase via G proteins. We did not observe any ef-
fect of ET-1 on adenylyl cyclase activity in a particulate frac-
tion of cells, in contrast to previous results in iris sphincter cells
(37) and vascular smooth muscle cells (38). Instead, our data
suggest that increases in PGE2 and PGI2 synthesis can ac-
count for ET-1–stimulated cAMP synthesis, as previously
shown in anterior pituitary gland (39) and alveolar epithelium
(40). The role of prostaglandins in the antiproliferative effect
of ET-1 was directly demonstrated by the growth inhibitory
properties of PGI2 and PGE2, and by the fact that ibuprofen
blocks ET-induced growth inhibition (Fig. 2). These data
agree with the growth inhibitory properties of PGE2 and PGI2
in several cell types, including rat activated HSC (41). Overall,
our findings demonstrate that in activated HSC, stimulation of
the ETB receptor increases the release of PGI2 and PGE2
with autocrine effects on adenylyl cyclase; the resulting eleva-
tion of cAMP induces growth inhibition (Fig. 7). Interestingly,
it has been shown that ETB receptor stimulation also causes
the release of PGE2 from Kupffer cells (42). Hence, it is
tempting to speculate that, in vivo, ET-1 could inhibit growth
of HSC by two pathways: on the one hand, by binding to ETB
receptors of activated HSC and by promoting the secretion of
prostaglandins with autocrine effects; and on the other hand,
by stimulating ETB receptors of Kupffer cells, thereby releas-
ing prostaglandins with paracrine effects on neighboring acti-
vated HSC.
ERK and JNK belong to the mitogen-activated protein ki-
nase family and define parallel cascades that lead to the phos-
phorylation of transcription factors involved in cell prolifera-
tion (26, 29–31). The ERK pathway is predominantly activated
by mitogens acting on receptor-protein tyrosine kinases or on
G protein–linked receptors (26, 31). The JNKs are activated
by stimuli that generally do not stimulate the ERK pathway
(29–31), such as cellular stress or inflammatory cytokines (35,
43, 44). However, JNK may also be activated by signals that
bind to tyrosine kinase receptors (22, 45) or to G protein–cou-
pled receptors (46, 47). While ERK activation is an early and
crucial event leading to mitogenesis (32), the function of JNK
is less clear and has been linked to cell proliferation (33–35),
cell transformation (48, 49), and apoptosis (50, 51). We previ-
ously reported that the growth inhibitory effect of ET-1 in
HSC is associated with a decrease of ERK stimulation by mi-
togenic agents (7). We now show that a promitogenic stimulus
also rapidly and markedly activates JNK, and that this effect is
strongly reduced in the presence of ET-1 (Fig. 4, A and B).
Moreover, its second messenger cAMP decreases activation of
both ERK and JNK (Fig. 5). The ability of cAMP to antago-
nize activation of ERK by growth factors generally correlates
with its growth inhibitory properties (52). The effect of cAMP
on JNK has been investigated in few reports that showed dis-
sociated regulation of ERK and JNK by the nucleotide (53,
54). Thus, in T lymphocytes, cAMP inhibited stimulation of
JNK and did not affect ERK activation (54). In contrast, in
gingival fibroblasts or HepG2, cAMP had no effect on activa-
tion of JNK, but inhibited activation of ERK (53). The fact
that ET-1 and cAMP reduce activation of both ERK and JNK
in activated HSC (Fig. 7), suggests that the blockade of both
pathways might be important for growth inhibition. Our re-
sults also emphasize the fact that a single factor may regulate
both ERK and JNK in selected cell types, either positively, as
shown with angiotensin II (47), carbachol (46), or EGF (22,
44), or negatively as observed with ET-1 in human HSC.
In contrast to the antiproliferative effects of ET-1 in acti-
vated human HSC, promitogenic effects of the peptide have
been described in several cells (6). While growth inhibition is
mediated by the ETB receptor (7), ET-1 stimulates cell prolif-
eration via ETA receptors (6). Therefore, the ratio between
ETA and ETB receptors might constitute an additional factor
that could affect the sensitivity of cells to the growth regula-
tory effects of ET-1. We found that prolonged treatment with
prostaglandins or forskolin increases the total number of ET
binding sites by fivefold. This upregulation affects predomi-
nantly the expression of ETB receptors, which increase from
50% in control cells to 80% in treated cells (Fig. 6 C). The se-
lective upregulation of ETB receptors by prostaglandins/
cAMP suggests the possibility of a positive feedback loop that
could amplify the growth inhibitory effect of ET-1 (Fig. 7). In
keeping with this hypothesis, it has been shown that upregula-
tion of ET receptors by cAMP is correlated with an enhanced
responsiveness to ET-1 in vascular smooth cells (55).
Proliferation of activated HSC is well documented in ex-
perimental chronic liver injury (56, 57) and constitutes one of
the elements that may contribute to the increased deposition
of extracellular matrix during chronic liver disease. Therefore,
there is growing interest in factors that may limit proliferation
of activated HSC (58, 59). It was recently shown by combined
Figure 7. Antiproliferative effect of ET-1 in activated HSC: a hypo-
thetical scheme.
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immunocytochemistry and in situ hybridization that, while ET-1
is weakly expressed in sinusoidal endothelial cells of the nor-
mal human liver, expression of the peptide is markedly en-
hanced in cirrhotic liver, and colocalizes with endothelial cells,
activated HSC, and bile duct epithelial cells (16). There are
currently no data regarding the in vivo pattern of expression of
ETA and ETB receptors in HSC, either in normal liver or dur-
ing chronic liver disease. However, in human HSC in culture,
there is a shift from a preponderance of the ETA receptor sub-
type to a predominant ETB subtype after cell passaging (16).
Therefore, increased expression of ET-1 during fibrogenesis
and selective upregulation of ETB receptors in activated HSC
suggest that the peptide could limit the proliferation of acti-
vated HSC during chronic liver disease. Moreover, the fact
that cAMP inhibits growth of activated human HSC suggests
that pharmacological activators of adenylyl cyclase or inhibi-
tors of phosphodiesterases might be of interest to counteract
the development of fibrosis in vivo.
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